
Colgate-Palmolive Co CL shares are trading higher in premarket on Friday after the first-quarter FY25 earnings report.
The company’s first-quarter FY25 sales declined 3% year over year to $4.91 billion, beating the analyst consensus estimate of $4.86 billion.
Organic sales increased by 1.4%. Total Oral, Personal, and Home Care net sales increased by 6.8% to $3.96 billion.
Non-GAAP EPS of $0.91 beat the consensus estimate of $0.86.
Also Read: PepsiCo CEO Warns Of Tariffs Led ‘Increase In Supply Chain Costs,’ Cuts Annual Profit Outlook
Colgate’s gross profit was $2.98 billion, while the margin expanded 80 basis points to 60.8%. Selling, general and administrative expenses slipped 0.9% to $1.8 billion.
Operating margin expanded 120 basis points to 21.9%, and operating income increased 2.8% to $1.07 billion for the quarter.
As of March 31, the company had $1.11 billion in cash and equivalents, and its operating cash flow totaled $600 million.
“As we look ahead, uncertainty and volatility in global markets, including the impact of tariffs, remain challenging. We are confident in our strategy and will continue to execute with focus and agility to mitigate these factors and achieve our revised 2025 financial targets,” said Chairman, President, and CEO Noel Wallace.
Outlook FY25: Colgate expects net sales to be up in the low single digits, including a negative impact from foreign exchange in the low single digits.
The company anticipates organic sales growth to be 2% to 4%.
The current outlook is better from the last quarter, where it expected FY25 net sales to be roughly flat, including a mid-single-digit negative impact from foreign exchange.
On a non-GAAP basis, the company expects gross profit margin and advertising to be roughly flat as a percentage of net sales and earnings per share to be up in the low single digits.
Price Action: CL shares traded higher by 1.19% at $93.80 in premarket session at the last check on Friday.
Read Next:
Photo by EDSON DE SOUZA NASCIMENTO via Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.